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Many hemodialysis patients in Japan have symptoms of
depression, but whether those patients are treated
appropriately is unknown. As part of the Dialysis Outcomes
and Practice Patterns Study, data on symptoms of
depression, physician-diagnosed depression, prescribed
medications, and death were collected prospectively in
cohorts in Japan (n¼ 1603) and 11 other countries
(n¼ 5872). Symptoms of depression were as prevalent in
Japan as elsewhere, but in Japan a much smaller percentage
of patients had physician-diagnosed depression: only 2% in
Japan vs 17% elsewhere. Antidepressants were much less
commonly prescribed in Japan: only 1% in Japan vs 17%
elsewhere for patients with many and frequent symptoms of
depression, and 16% in Japan vs 34% elsewhere for patients
with physician-diagnosed depression. In Japan, symptoms
of depression were associated with prescription of
benzodiazepines (without antidepressants), and patients
with physician-diagnosed depression were twice as likely to
be given benzodiazepines: 32% in Japan vs 16% elsewhere.
Benzodiazepine monotherapy was associated with death
(relative risk 1.56, 95% confidence interval (CI), 1.25–1.94),
even after adjustments for 13 likely confounders (relative risk
1.27, 95% CI, 1.01–1.59). Hemodialysis patients in Japan with
symptoms of depression are given not antidepressants but
benzodiazepines, a practice associated with higher mortality.
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Depression in hemodialysis patients is underdiagnosed. In 12
countries participating in the Dialysis Outcomes and Practice
Patterns Study (DOPPS), the number of patients with high
scores on a standard questionnaire of symptoms of depres-
sion was more than three times the number in whom
depression had been diagnosed by a physician.1 Depression is
also undertreated: of the DOPPS patients with physician-
diagnosed depression, only about one-third had been given a
prescription for antidepressant medication, even though
symptoms of depression were associated with withdrawal
from treatment and with death.1
In Japan, underdiagnosis was much more common than in
any of the 11 other DOPPS countries,1 but at the time of that
study the data on medications given to DOPPS patients in
Japan were not available. We obtained those data, and examined
the prescription of antidepressants and benzodiazepines to
hemodialysis patients in Japan. We also studied whether those
prescriptions were associated with symptoms of depression,
physician-diagnosed depression, hospitalization, and death.
RESULTS
Symptoms of depression
Symptoms of depression were common among patients in
Japan: 40.0% had Center for Epidemiological Studies Depression
Screening Index (CES-D) scores of 10 or greater, and 14.4% had
scores of 15 or greater (Table 1). These did not differ markedly
from the other DOPPS countries overall (43.9 and 19.5%,
Table 1). Patients in Japan were no more or less likely than those
in the other countries to have high CES-D scores (adjusted odds
ratio, 0.97; 95% confidence interval (CI), 0.84–1.11).
Physician-diagnosed depression
Almost none of the patients in Japan had physician-
diagnosed depression (only 31 of 1603, 1.9%), but the
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comparable percentage in the other DOPPS countries was
more than 17% (Table 1). Patients in Japan were significantly
less likely than those in the other countries to have physician-
diagnosed depression (adjusted odds ratio, 0.14; 95% CI,
0.09–0.21).
In addition, the connection between symptoms of
depression and physician-diagnosed depression was weaker
in Japan than in the other countries: physicians in the other
countries diagnosed depression in 25.2% of patients with
high CES-D scores, but physicians in Japan did so in less than
3% of such patients (Table 1). Unlike in the other countries,
in Japan there was no clear association between CES-D score
and the diagnosis of depression (Figure 1a).
In Japan, the disparity between physician-diagnosed
depression and symptoms of depression did not differ by
the type of dialysis facility (private clinic vs hospital; 94.6 vs
92.4%; P40.05), but there was slightly less disparity in
institutions that had a department of psychiatry (psychiatry
department present vs absent; 86.7 vs 95.0%, Po0.05).
Prescription of antidepressants
In Japan, very few patients were given antidepressants (only 19
of 1603 patients, 1.2%). This was also true of those with high
CES-D scores (only eight of 642 patients, 1.2%). The
comparable percentages for the other DOPPS countries were
more than 10 times higher: 12.8 and 17.2% (Table 1, Figure 1b).
Even in patients with physician-diagnosed depression,
prescription of antidepressants was only half as common in
Japan as in the other countries: 16.1 vs 33.7% (Table 1).
Prescription of benzodiazepines
Benzodiazepines were prescribed to about one-fifth of the
patients in Japan and to about one-seventh of those in the
other DOPPS countries (Table 1). In Japan, patients with
physician-diagnosed depression were twice as likely as those
in the other countries to be given benzodiazepines: 32.3 vs
15.7% (Table 1).
Unlike in the other countries, in Japan patients who had
high CES-D scores were almost twice as likely as those with
lower scores to be given benzodiazepines: 26.6 vs 14.3%
(Table 1). The association between CES-D scores and
prescription of benzodiazepines was stronger in Japan than
in the other countries (Figure 1c).
Within Japan, patients who received benzodiazepines had
lower five-item mental health index scores (indicating more
symptoms of depression; adjusted odds ratio, 0.984, 95% CI,
0.980–0.988), but benzodiazepine prescription was not asso-
ciated with albumin concentration (an indicator of end-stage
renal disease severity; adjusted odds ratio, 0.906, 95% CI,
0.737–1.114).
Benzodiazepine prescribing practice also varied among
dialysis facilities in Japan. At nine of the 59 facilities studied,
Table 1 | Symptoms of depression, physician-diagnosed depression, and medications in hemodialysis patients in Japan
and in the 11 other DOPPS countriesa
Percent or mean7s.d. (n/N)
Japan Other DOPPS countries
Measure N=1603 N=5872
CES-D score 9.175.2, median=8 9.375.9, median=8
0–4 18.0 (289/1603) 22.9 (1346/5872)
5–9 41.9 (672/1603) 33.0 (1938/5872)
10–14 25.6 (410/1603) 24.4 (1430/5872)
15–19 9.5 (153/1603) 13.5 (795/5872)
20–24 4.2 (67/1603) 5.0 (295/5872)
25–30 0.7 (12/1603) 1.0 (59/5872)
MHI-5 score 65.3721.9, median=65.0 Not measured
Prevalence of
CES-D score X10 40.0 (642/1603) 44.0 (2582/5872)
MHI-5 score o60 38.0 (564/1485) Not measured
Physician-diagnosed depression 1.9 (31/1603) 17.4 (1020/5872)
Physician-diagnosed depression in those with CES-D score X10 2.3 (15/642) 25.2 (650/2582)
Ratio of CES-D X10 to physician-diagnosed depression 20.7 2.5
Antidepressants
Overall 1.2 (19/1603) 12.8 (750/5872)
In those with CES-D score X10/o10 1.2 (8/642)/1.1 (11/961) 17.2 (444/2582)/9.3 (306/3290)
In those with/without physician-diagnosed depression 16.1 (5/31)/0.9 (14/1572) 33.7 (344/1020)/8.4 (406/4852)
Benzodiazepines (without antidepressants)
Overall 19.2 (308/1603) 14.8 (869/5872)
In those with CES-D score X10/o10 26.6 (171/642)/14.3 (137/961) 17.5 (452/2582)/12.7 (417/3290)
In those with/without physician-diagnosed depression 32.3 (10/31)/19.0 (298/1572) 15.7 (160/1020)/14.6 (709/4852)
CES-D, Center for Epidemiological Studies-Depression Scale; DOPPS, Dialysis Outcomes and Practice Patterns Study; MHI-5, five-item mental health index.
aDOPPS II data (2002–2004), in prevalent cross-section of patients with information on physician-diagnosed depression, symptoms of depression, and medications (N=7475).
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no more than 10% of the patients with high CES-D scores
were given benzodiazepines, but at 11 facilities more than
40% of the patients with high CES-D scores were given these
drugs (Figure 2). Japan had many facilities where patients
with high CES-D scores were likely to be given benzodiaze-
pines, but in the other countries such facilities were rare.
Benzodiazepine prescribing practice was more uniform
among dialysis facilities in the other countries than among
facilities in Japan.
Adverse outcomes
CES-D scores were positively associated with the risk of
hospitalization and of death (Figure 3). Having received a
prescription for a benzodiazepine was not associated with the
risk of hospitalization, but it was associated with the risk of
death (Table 2). That association remained even after
adjusting for depression, and after adjusting for demographic
and socioeconomic characteristics, time on dialysis, comor-
bid conditions, albumin, eKt/V, and hemoglobin (Table 2).
The risk of death was also greater at dialysis facilities that
were above the median for the percentage of patients given
benzodiazepines (hazard ratio, 1.36, 95% CI, 1.03–1.79).
DISCUSSION
Diagnosis of depression
The discrepancy between symptoms of depression and
physician-diagnosed depression is greater in Japan than in
other countries (Table 1, Figure 1a).1 To interpret this
finding, we note first that the social stigmatization in Japan of
people given the diagnosis of depression is well known.2–6 In
addition, a reluctance to identify depression can be found
among the general public: when Japanese and Australians
were given a vignette of someone with clear signs and
symptoms of clinical depression and then asked to describe
that person’s condition, the Japanese were only one-third as
likely as the Australians to use the term ‘depression’.7 In
Japan, symptoms of depression may even ‘be given positive
social meanings’.8 The Diagnostic and Statistical Manual is
available in Japanese, but remaining to be studied in
sufficient depth are the diagnostic criteria actually used by
Japanese physicians when they encounter patients with
symptoms of depression, how such practices differ between
countries, and how they differ between physicians of different
educational and clinical backgrounds. The relations of
psychiatrists to their patients are changing,9 and recognition
and treatment of depression is improving among specialist
providers of psychiatric services,10 but nephrologists, even
those who recognize clinical depression, might still not
record the diagnosis.
Symptoms of depression are often somatic,3,6,11 and
because renal failure affects many systems, nephrologists’
task of distinguishing somatic symptoms of depression from
‘direct’ effects of renal failure is particularly complex. This
might be alleviated if medical students and postgraduate
trainees received better training in the diagnosis of mild and
moderately severe psychiatric conditions.
One might expect the presence of a psychiatrist to make
the diagnosis of depression more likely, and the present data
do support that idea: in patients with high CES-D scores the
diagnosis of depression was more common at dialysis
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Figure 1 | (a–c) Percentages of patients with physician-diagnosed
depression (a), and percentages given prescriptions for anti-
depressants (b), and benzodiazepines (without antidepressants)
(c), by CES-D score; data from Japan and from the 11 other
DOPPS countries. DOPPS II data (2002–2004); restricted to a
prevalent cross-section of patients with information on depression
diagnosis or medications, and who had completed a CES-D
instrument.
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facilities in institutions with a department of psychiatry. Such
facilities accounted for one-quarter of the facilities studied in
Japan. Thus, the percentage of hemodialysis patients to
whom psychiatric services were readily available was small.
Of course, even if a psychiatrist is available and a patient is
given a referral, the patient can still refuse consultation or
treatment. The majority of people in Japan who experience a
severe or moderate mental disorder do not seek medical
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Figure 3 | (a, b) Adjusted relative risks of all-cause mortality
(a) and of hospitalization (b) by category of CES-D score
(DOPPS II data (2002–2004), Japan only, restricted to patients
completing a patient questionnaire). All models control for effects
of facility clustering and were adjusted for age, sex, time on dialysis,
socioeconomic factors, comorbid conditions, hemoglobin, serum
albumin, eKt/V, and prescription of antidepressants (n¼ 1938).
Table 2 | Associations between benzodiazepine prescription and the risks of death and of hospitalizationa
Relative riskb (95% CI)
P-values
Adjustment level Mortality Hospitalization
1. Unadjusted 1.56 (1.25–1.94) 1.14 (1.01–1.28)
o0.001 0.03
2. Adjusted for MHI-5 score 1.37 (1.09–1.72) 1.05 (0.93–1.19)
0.007 0.42
3. Same as no. 2 above, but also adjusted for age, sex, time on dialysis, 1.26 (41.00–1.59) 0.99 (0.87–1.12)
socioeconomic variables, and comorbid conditions 0.05 0.84
4. Same as no. 3 above, but also adjusted for albumin, eKt/V, and hemoglobin 1.27 (1.01–1.59) 0.99 (0.88–1.12)
0.04 0.91
CI, confidence interval; MHI-5, five-item mental health index.
aJapan DOPPS I and II data (1999–2004, N=5041); models stratified by phase of DOPPS data collection, adjusted as described above, and controlled for effects of facility
clustering.
bRisks of hospitalization and of death in patients given prescriptions for benzodiazepines and not antidepressants, relative to the risk in patients given neither
benzodiazepines nor antidepressants.
The numbers in italics are P-values.
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Figure 2 | Variation in practice patterns among dialysis facilities
in Japan and in the other DOPPS countries, showing differences
among dialysis facilities with regard to the strength of the
association between symptoms of depression and prescription of
benzodiazepines (in patients who were not given prescriptions
for antidepressants). The y axis indicates the percentage of facilities
at which a given percentage of patients with CES-D scores of 10 or
greater received prescriptions for benzodiazepines. For example, if a
dialysis facility had 28 patients with CES-D scores of 10 or greater, and
benzodiazepines were prescribed to 16 of those 28 patients (57%),
then that facility would be included in the category ‘450–60’. In the
present study, at 15.2% of dialysis facilities in Japan no more than
10% of the patients with high CES-D scores were given benzodia-
zepines, while at almost half of the facilities in Japan (49.2%; i.e.
30.5þ 11.9þ 5.1þ 1.7) at least 30% of patients with high CES-D
scores were given benzodiazepines. Facilities where benzodiazepines
were prescribed to many of the patients with high CES-D scores were
rare in the other DOPPS countries but they were common in Japan.
Benzodiazepine prescribing practice was also more uniform in the
other DOPPS countries than in Japan.
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treatment.12 One reason may be found in the 2006 report by
Shima and Satoh,6 who noted that the stigma mentioned
above ‘continues to be associated with those suffering from
mental disorders and for those who have to consult a
psychiatrist’. In addition, among the general public in Japan
psychiatrists are not commonly mentioned as people who
would be helpful to someone with symptoms of depression:
psychiatrists ranked fifth, behind counselors, close family,
close friends, and social workers.7
Underprescription of antidepressants
In the other DOPPS countries, antidepressants were pre-
scribed to one-third of the patients with physician-diagnosed
depression, but in Japan the comparable fraction was about
one-sixth (Table 1). That is, even after diagnosing depression,
physicians in Japan were only half as likely to prescribe
antidepressants as were physicians in other countries.
Prescription of antidepressants is tied to socioeconomic
and cultural forces,8,13 with the result that, in Japan,
antidepressants are prescribed to patients with diagnosed
depression at dosages that are below international stan-
dards.14 That being the case in psychiatric settings,14
physicians without psychiatric training may be even more
reluctant to prescribe these drugs. Nephrologists might be
unsure about the most appropriate doses and regimens, and
about monitoring patients who receive antidepressants. The
limited availability of psychiatric services (noted above) and
reluctance to refer patients to outside institutions would
make prescription of antidepressants even less likely.
Nephrologists might also avoid prescribing antidepres-
sants because of anticholinergic effects: dry mouth could
interfere with the restriction of fluid intake. Increased fluid
intake might be seen as more dangerous than suboptimal treat-
ment of recognized depression, but why that would be true
only in Japan is unclear. We also note that the hypothesis that
increased use of antidepressants would improve outcomes
remains to be tested.
Possible substitution of benzodiazepines for antidepressants
We could not directly test the hypothesis that benzodiaze-
pines were substituted for antidepressants, but the results in
Table 1 and in Figures 1b, c, and 2 show that patients who
might be expected to benefit from antidepressants were given
not antidepressants but benzodiazepines. The benzodaize-
pines prescribed without antidepressants to those patients
may have been intended as treatment, however inappropriate,
for depression. They might also have been prescribed to treat
pruritus, insomnia,15 or anxiety. Even the possibility that
some symptoms of depression reported by dialysis patients
result from, or are aggravated by, benzodiazepine use should
be considered.10,16
In Japan, when members of the general public were asked
which drugs would be helpful for someone with symptoms of
depression, about 30% indicated ‘sleeping pills’ and about
40% indicated ‘tranquilizers’.7 This public opinion is
consistent with Japanese medical practice. Specifically,
benzodiazepines are prescribed not only to about half of
patients with depression who are under psychiatric care,14
but also to patients with depressed mood who are seen in
primary care.8,10
Because benzodiazpines are not indicated in the treatment
of depression per se,17,18 one would expect to find only a few
dialysis facilities where they were prescribed to large
percentages of patients with high CES-D scores. That is
exactly the pattern found in the countries other than Japan.
In contrast, at many Japanese facilities benzodiazepines were
prescribed to large percentages of such patients, which is
consistent with the hypothesis that in Japan benzodiazepines
are prescribed to treat symptoms of depression (Figure 2).
The practice of prescribing benzodiazepines to patients
with symptoms of depression varied more widely among
dialysis facilities in Japan than in other countries. Whether
the variation in prescribing practice within Japan is related to
variation in case mix, physician training, or other character-
istics of the facilities remains to be studied, as does the
hypothesis that the nine Japanese facilities at the left end of
the x axis in Figure 2 should serve as models of good
prescribing practice.
Adverse outcomes, and overall conclusions
Having a high CES-D score is a risk factor for hospitaliza-
tion1,19 and for death among hemodialysis patients world-
wide.1 The present results show that symptoms of depression
are important risk factors for those outcomes in Japanese
patients in particular (Figure 3). Another new finding of the
present study is that prescription of a benzodiazepine
without prescription of an antidepressant is a risk factor
for death. Benzodiazepines might have been prescribed as
palliative care when patients were severely ill and already near
death, but if such ‘confounding by indication’ did occur its
effects were small: albumin concentration (an indicator of
disease severity) was not associated with benzodiazepine
prescription; facility-level analysis20 also showed an associa-
tion between benzodiazepines and the risk of death; and even
after adjustment for age, albumin, comorbidities, and other
likely confounders, the benzodiazepine–death association
remained (Table 2). Although evidence reported recently
suggests that symptoms of depression develop as a response
to physical deterioration,21 we must still be concerned about
the dangers of not treating depression and of treating it
inappropriately. For example, of great concern is the
possibility that underlying the benzodiazepine–death associa-
tion is a cause–effect relationship. Benzodiazepine-related
deaths might be caused by these drugs’ adverse cognitive and
psychomotor effects.17,22,23 We are now planning a case-by-
case study of benzodiazepine prescription and causes of
death.
Taken together, these findings suggest that outcomes could
be improved if, as a minimum, dialysis patients with
symptoms of depression are not given benzodiazepines
inappropriately: primum non nocere. Hemodialysis clinics in
Japan already have mortality rates that are much lower than
1870 Kidney International (2006) 70, 1866–1872
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those in the US and Europe.24 Reconsideration of benzodia-
zepine prescribing practice, and of the treatment of patients
who have symptoms of depression, might further reduce
mortality.
We studied only dialysis patients, but depression is known
to be a risk factor for death in patients with other chronic
conditions as well,25,26 so the results regarding medications
might be generalized to others. In general medical practice in
Japan, the diagnosis of depression is not common3–6,12 and
benzodiazepines are prescribed to patients who would
probably be given antidepressants if they were in Western
countries.8,10,14 Thus, even in patients not receiving dialysis,
some prescriptions for benzodiazepines may need to be
re-evaluated.
MATERIALS AND METHODS
Data were gathered between 1999 and 2004 in phases I and II of the
DOPPS, an international, prospective, observational study of
hemodialysis practice patterns and associated outcomes in Australia,
Belgium, Canada, France, Germany, Italy, Japan, New Zealand,
Spain, Sweden, the United Kingdom, and the United States.27
Nationally representative samples of hemodialysis facilities were
recruited in each country. Within each facility, study patients were
randomly selected. Institutional review boards in each country
approved the study, and informed consent was obtained from
patients in accord with local requirements.
Baseline data regarding demographic factors, comorbid condi-
tions, laboratory values, years since the onset of end-stage renal
disease, and dialysis dose by equilibrated Kt/V (eKt/V) were
collected upon patient entry into the study. Each patient’s medical
record was assessed for physician-diagnosed depression within the
past 12 months. This was recorded along with the listed name,
dosage, and frequency of any medication(s) prescribed on or before
entry into the study.
Patients entering phase II of the DOPPS were asked to complete
the 10-item version of the CES-D, which was used to quantify the
number and frequency of symptoms of depression during the past
week.28,29 Each response is coded on a scale from 0 to 3; the CES-D
score (0–30) is the sum of the item scores. Higher scores indicate
more symptoms, and more frequent symptoms, of depression. High
CES-D scores were defined as those X10.1,29,30 As another measure
of symptoms of depression, the five-item mental health index of the
SF-3631–33 was completed by patients in both the DOPPS I and
DOPPS II in Japan.
Primary analyses involving baseline patient characteristics were
restricted to the initial prevalent cross-sectional sample of 1603
DOPPS II Japanese patients with information on depression
diagnosis and a calculable CES-D score. We also compared the
Japanese sample with a similarly sampled initial cross-section of
5872 patients from the other DOPPS countries. Statistical modeling
for time-to-event analyses utilized the entire DOPPS II Japanese
sample of 1938 patients.
Logistic regression techniques were used to estimate associations
between baseline patient characteristics and indicators of depres-
sion. Univariate models involving only one explanatory variable
were calculated for physician-diagnosed depression, because its
prevalence was low. For associations with patient-reported symp-
toms of depression, we used multivariate models accounting for
clustering and adjusted for age, sex, years on dialysis, living
arrangement status, marital status, educational attainment, employ-
ment status, household income, 12 summary comorbid conditions,
eKt/V, hemoglobin, and serum albumin.
Cox proportional hazards models were used to examine
associations between indicators of depression and outcomes
(hospitalization and all-cause mortality). Withdrawal from dialysis
was not analyzed because the number of events was too low (only
eight in Japan). Except where noted otherwise, all models accounted
for clustering effects and were adjusted for the variables listed above.
Analyses of benzodiazepine prescription as a predictor of
hospitalization and of death were also performed with Cox
proportional hazards models, using data from Japan DOPPS I and
II (n¼ 5041). As indicated in Table 2, four models were used:
(1) unadjusted; (2) adjusted for the five-item mental health index
score; (3) same as no. 2, but also adjusted for age, sex, time on
dialysis, socioeconomic factors (living alone, married, educational
status, employment status, and household income), and the
presence or absence of 12 comorbid conditions; and (4) same as
no. 3, but also adjusted for serum albumin, hemoglobin, and eKt/V.
Logistic regression with benzodiazepine prescription as the outcome
also included the variables mentioned above.
We considered prescription of an antidepressant to indicate that
clinical depression had been recognized and was being treated as
such. When analyzing prescription of benzodiazepines, we wanted
to focus on patients in whom clinical depression either was not
recognized or was not treated with antidepressant medication.
Therefore, results regarding prescription of benzodiazepines do not
include data from patients treated with both benzodiazepines and
antidepressants.17,34
To quantify disparities between symptoms of depression and
physician-diagnosed depression at the facility level, we computed
1 minus the ratio of the number of patients at the facility with
physician-diagnosed depression to the number at the same facility
with a CES-D score of 10 or greater, and expressed the result as a
percentage. For each facility, to the degree that the number of
patients with high CES-D scores exceeds the number with physician-
diagnosed depression, the value of this ‘disparity index’ for that
facility approaches 100%.
All statistical analyses were performed with SAS software, version
9.1 (SAS Institute; Cary, NC, USA).
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